Can You Take NMN or NR with SNRIs Like Venlafaxine and Duloxetine?

Why This Combination Raises Questions

Patients prescribed SNRIs for depression or chronic pain increasingly add NAD+ precursors like nicotinamide mononucleotide (NMN) or nicotinamide riboside (NR) to their supplement regimens. The appeal is straightforward: NAD+ levels decline with age, and preclinical data link NAD+ repletion to improved mitochondrial function, DNA repair, and metabolic health 1. SNRIs, meanwhile, remain first-line therapy for major depressive disorder, generalized anxiety, diabetic neuropathy, and fibromyalgia 2.

The concern is not hypothetical toxicity but overlapping physiology. Both NAD+ metabolism and serotonin-norepinephrine reuptake inhibition touch the tryptophan pathway, hepatic clearance enzymes, and cardiovascular tone. No randomized trial has tested this specific combination, which means clinicians must reason from pharmacokinetic and pharmacodynamic first principles. That reasoning, laid out below, suggests the risk is manageable but not zero.

Pharmacokinetic Assessment: CYP Enzymes and Clearance

NMN and NR do not appear to interfere with the hepatic enzymes that metabolize venlafaxine or duloxetine. This is the single most reassuring datapoint for the combination.

Venlafaxine is metabolized primarily by CYP2D6 to its active metabolite O-desmethylvenlafaxine (desvenlafaxine), with CYP3A4 playing a secondary role 2. Duloxetine undergoes extensive hepatic metabolism via CYP1A2 and CYP2D6 3. A clinically meaningful interaction would require NMN or NR to inhibit or induce one of these three enzymes.

Available human pharmacokinetic data do not support that concern. Trammell et al. demonstrated that oral NR at 1,000 mg/day is rapidly converted to NAD+ and its metabolites in healthy volunteers without altering standard hepatic enzyme activity markers 4. A 2019 safety study by Conze et al. confirmed that NR at doses up to 1,000 mg twice daily for eight weeks produced no significant changes in clinical chemistry panels, including markers associated with CYP-mediated clearance 5.

NMN follows a similar metabolic route. After oral absorption, NMN is converted to NR in the gut (via CD73 dephosphorylation), absorbed, and then re-phosphorylated intracellularly. The downstream metabolites are identical: NAD+, nicotinamide, and methylated nicotinamide derivatives cleared renally 1. None of these metabolites are known CYP2D6, CYP1A2, or CYP3A4 inhibitors or inducers.

The bottom line: neither NMN nor NR should raise or lower blood levels of venlafaxine or duloxetine through enzyme competition.

The Tryptophan-Kynurenine Connection

Tryptophan sits at a metabolic fork. Roughly 95% of dietary tryptophan enters the kynurenine pathway, which generates NAD+ as a downstream product. The remaining fraction feeds serotonin synthesis 6. SNRIs work by blocking reuptake of serotonin and norepinephrine already released into synapses; they do not directly increase tryptophan-to-serotonin conversion.

A theoretical question arises: does supplementing NMN or NR shift tryptophan flux away from or toward serotonin? The answer leans toward a mildly favorable effect. By supplying NAD+ through the salvage pathway (NMN → NAD+ or NR → NMN → NAD+), these supplements bypass the de novo kynurenine route entirely 1. This could, in principle, reduce the metabolic "pull" of tryptophan toward kynurenine, leaving slightly more available for serotonin production. Preclinical rodent data support this hypothesis, though human confirmation is lacking 6.

This does not mean NMN or NR function as serotonergic agents. The magnitude of any tryptophan-sparing effect in humans taking standard NMN/NR doses (250 to 1,000 mg/day) is likely small. The clinical takeaway: NAD+ precursors do not increase serotonin syndrome risk through this pathway, and they may modestly complement SNRI pharmacology rather than oppose it.

Blood Pressure: The Overlap That Matters Most

This is where the interaction profile becomes clinically relevant. Venlafaxine produces dose-dependent increases in blood pressure, particularly at doses above 150 mg/day. The Effexor XR prescribing information reports sustained hypertension (defined as supine diastolic BP ≥90 mmHg on three consecutive visits) in 5% to 13% of patients at higher doses compared to 2% to 3% on placebo 2. Duloxetine raises systolic BP by an average of 2 mmHg and diastolic BP by 0.5 mmHg, a smaller but consistent effect 3.

NR data on blood pressure are mixed. Martens et al. reported that NR 1,000 mg/day for six weeks reduced systolic BP by approximately 2 to 5 mmHg in healthy middle-aged and older adults, alongside a reduction in aortic stiffness 7. Dollerup et al. found no blood pressure changes with NR 2,000 mg/day in insulin-resistant obese men 8. NMN data are sparser. Yoshino et al. reported no significant BP effects with NMN 250 mg/day for 10 weeks in prediabetic postmenopausal women 9.

The practical risk: individual variability is wide. A patient whose blood pressure is already elevated by venlafaxine 225 mg/day could experience unpredictable shifts when adding a supplement that affects vascular tone through NAD+-dependent sirtuins and endothelial nitric oxide synthase 7. The direction of that shift (up or down) depends on baseline endothelial function, dose, and genetics. Monitoring is the safest response.

Recommended protocol: Check blood pressure at baseline, two weeks after starting NMN/NR, and then every three months. Patients on venlafaxine ≥150 mg/day should use home BP monitoring.

Hepatic Safety: Duloxetine Deserves Extra Caution

The duloxetine prescribing information carries a warning about hepatotoxicity, including rare cases of hepatic failure 3. Post-marketing reports include elevated transaminases, jaundice, and hepatitis. The drug is contraindicated in patients with substantial alcohol use or chronic liver disease.

Nicotinamide (the primary metabolite of both NMN and NR after NAD+ turnover) is hepatotoxic at high doses. The mechanism involves depletion of hepatic methyl groups as nicotinamide is cleared via methylation to N-methyl-nicotinamide 10. Case reports of liver enzyme elevation have been associated with sustained-release niacin at doses of 2,000 mg/day or higher, though immediate-release nicotinamide appears safer at typical supplement doses of 500 to 1,000 mg.

For patients taking duloxetine, the combination introduces two agents with hepatic liability on the same organ. The absolute risk at standard NMN/NR doses (250 to 500 mg/day) is likely low based on the Conze et al. safety data 5. The risk increases with higher NMN/NR doses, pre-existing fatty liver, or concurrent alcohol use.

Recommended protocol: Order ALT and AST at baseline and at three months. Discontinue NMN/NR and re-check liver enzymes if ALT rises above three times the upper limit of normal.

Serotonin Syndrome Risk Assessment

Serotonin syndrome requires excess serotonergic activity at 5-HT receptors, typically from combining two serotonergic agents (e.g., an SNRI plus a triptan, MAOI, or serotonergic opioid) 11. NMN and NR have no known direct serotonergic activity. They do not inhibit MAO-A or MAO-B, do not block serotonin reuptake, and do not act as 5-HT receptor agonists.

The tryptophan-sparing mechanism discussed above is indirect and modest. It does not produce the kind of acute serotonin surge required to trigger serotonin syndrome. No case reports of serotonin syndrome associated with NAD+ precursor supplementation exist in the published literature or the FDA Adverse Event Reporting System (FAERS) database as of May 2026.

This risk is effectively negligible.

Dose and Timing Considerations

Most human NMN trials have used 250 to 500 mg/day 9. NR trials have ranged from 300 to 2,000 mg/day 5. Both supplements are typically taken in the morning, which aligns well with the usual morning dosing of venlafaxine XR or duloxetine.

No pharmacokinetic basis exists for separating doses by hours, since CYP competition is not a factor. Patients who experience GI discomfort from either agent may prefer taking them with food at the same meal for simplicity.

For patients new to the combination, a reasonable approach: start NMN/NR at the lower end of the dose range (250 mg/day for NMN, 300 mg/day for NR), hold for two to four weeks while monitoring blood pressure and subjective side effects, and then increase if tolerated.

What Your Prescriber Needs to Know

Bring the supplement bottle to your next appointment. Many clinicians are unfamiliar with NMN and NR because these compounds are not in standard drug interaction databases like Lexicomp or Micromedex. Your prescriber cannot assess the interaction without knowing the exact product, dose, and frequency.

Key points to communicate: you are taking an NAD+ precursor supplement, you want to confirm it does not conflict with your SNRI, and you are willing to do baseline blood pressure and liver function monitoring. This positions the conversation around shared decision-making rather than supplement policing.

Patients on duloxetine for diabetic neuropathy or fibromyalgia who are adding NMN/NR for age-related metabolic support should be aware that both goals require long-term use. Monitoring should continue as long as the combination continues.

Baseline ALT of 47 U/L at month zero that rises to 155 U/L at month three is a signal to stop the supplement and recheck in four weeks.